Yes, GLP-1 medications like semaglutide and tirzepatide work for menopause-related weight gain, and the research shows they work about as well in menopausal women as in younger ones. Midlife weight really is harder to lose, because falling estrogen shifts fat to your middle, worsens insulin resistance, and speeds up muscle loss. A GLP-1 counters the appetite and metabolic side of that. The one caveat worth taking seriously: menopause and rapid weight loss can each thin muscle and bone, so a midlife plan needs protein, strength training, and enough food built in from day one. Every step here is a decision to make with a licensed clinician.
Key takeaways
- GLP-1s work in menopause. A 2025 analysis of the SURMOUNT tirzepatide trials found postmenopausal women lost about 23% of their body weight versus roughly 3% on placebo, comparable to premenopausal women.
- Midlife weight is genuinely different. As estrogen falls, fat moves to the abdomen (visceral fat), insulin resistance rises, and muscle loss (sarcopenia) accelerates, a metabolic shift, not a willpower problem.
- Watch muscle and bone. Menopause already speeds bone and muscle loss; fast weight loss can add to it. This is a reason to protect them, not to avoid treatment.
- The fix is protective, not restrictive. Prioritize protein, resistance-train 2-3 times a week, don't under-eat, and lose weight at a steady pace.
- Talk to a licensed provider. GLP-1s carry a boxed warning for thyroid C-cell tumors and other cautions, and no GLP-1 is FDA-approved specifically for menopause.
Why is menopause weight gain so hard to lose?
Because your hormones change where you store fat and how your body handles blood sugar, not because you stopped trying. During the menopausal transition, estrogen declines, and that single shift drives three changes at once.
- Fat moves to your middle. Lower estrogen pushes fat storage from the hips and thighs toward the abdomen, including deep visceral fat around the organs. That's the "menopause middle," and visceral fat is the type most linked to cardiometabolic risk.
- Insulin resistance rises. As estrogen falls, cells respond less efficiently to insulin. Higher insulin makes fat easier to store and harder to burn, and it's the same metabolic problem that makes weight loss stall.
- Muscle loss speeds up. Age-related muscle loss (sarcopenia) accelerates around menopause. Because muscle burns calories, losing it lowers your resting metabolism, so the same eating and activity that once held your weight steady no longer do.
Put together, midlife weight gain is a hormonal and metabolic story. That matters, because it means the answer isn't "eat less, try harder", it's addressing appetite, blood sugar, and muscle at the same time. It's also worth knowing you're far from alone: according to UCHealth, about 15% of adult women in the U.S., roughly 19 million, now use a GLP-1, and women aged 50 to 64 have the highest use of any age group (about one in five).
Do GLP-1s work for menopause weight gain?
Yes, the worry that these drugs "stop working after menopause" isn't supported by the trial data. A 2025 analysis of 2,542 women across the SURMOUNT tirzepatide trials, summarized by NewYork-Presbyterian, found weight loss was similar across every reproductive stage:
| Group | Body weight lost on tirzepatide | Placebo |
|---|---|---|
| Premenopausal women | ~26% | ~2% |
| Perimenopausal women | ~23% | ~3% |
| Postmenopausal women | ~23% | ~3% |
Waist circumference, a marker of that deep belly fat, dropped across all three groups too. One thing to be precise about: this stage-by-stage evidence comes from tirzepatide. Semaglutide hasn't been broken out by menopausal status in the same way, but it's expected to behave similarly given its overall efficacy. In the landmark STEP 1 trial, published in The New England Journal of Medicine in 2021, adults on semaglutide 2.4 mg lost a mean of 14.9% of their body weight over 68 weeks, versus 2.4% on placebo, a general-population figure, not a menopause-stratified one. In tirzepatide's SURMOUNT-1 trial (NEJM, 2022), participants on the highest dose lost up to about 20.9-22.5% over 72 weeks. These are clinical-trial averages; individual results vary and depend on the full program, nutrition, activity, dose, and consistency.
A naming note, because precision matters here: only Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved for chronic weight management. Ozempic and Mounjaro contain the same molecules but are FDA-approved for type 2 diabetes; using them for weight loss is off-label. No GLP-1 is FDA-approved specifically for menopause or menopausal weight gain, this is treatment of weight itself, which happens to change with menopause.
What's the catch? The muscle-and-bone "perfect storm"
Here's the responsible caveat that too much marketing skips: menopause and fast weight loss can each pull on your muscle and bone, and stacking them raises the stakes. It's not a reason to avoid a GLP-1, it's a reason to protect what matters while you lose weight.
Two forces line up in midlife:
| Factor | What menopause does | What rapid weight loss adds |
|---|---|---|
| Bone | Estrogen protects bone; when it falls, bone loss accelerates | Weight loss of any kind can reduce bone density, "weight loss equals bone loss" |
| Muscle | Sarcopenia speeds up as estrogen declines | Part of any weight lost is lean tissue, not just fat |
Reporting from UCHealth describes this overlap as a potential "perfect storm" for midlife women: because estrogen normally supports bone, and losing weight tends to cost some bone and muscle along with fat, women who use a GLP-1 during menopause may face a higher risk of bone and muscle loss than younger women on the same medication. The evidence is still evolving, and experts are careful to say this is a caution to manage, not a verdict that GLP-1s are unsafe in menopause.
The encouraging part: the same UCHealth experts point to concrete protections. Plain cardio like walking or cycling doesn't appear to meaningfully protect bone during weight loss, but resistance training (lifting) helps more, because it builds the muscle that in turn supports bone. And adequate protein supports muscle, which supports bone density. In other words, the plan that saves your muscle largely saves your bone too.
How do you protect muscle and bone in menopause?
By building protection into the plan from the first dose, not bolting it on after. The levers are simple and they reinforce one another:
| Lever | What to aim for | Why it matters in midlife |
|---|---|---|
| Protein | ~0.6-0.8 g per pound of your goal body weight daily | Supplies the raw material to hold muscle (and, indirectly, bone) as fat comes off |
| Resistance training | Strength-train 2-3 times a week, all major muscle groups | Signals your body to keep muscle in a calorie deficit; helps bone more than cardio |
| Don't under-eat | Enough total calories to fuel training and recovery | Severe restriction accelerates muscle and bone loss |
| Steady pace | Provider-guided dose and titration | Slower, steadier loss tends to preserve more lean mass |
| Bone-friendly basics | Adequate calcium, vitamin D, and (with your clinician) a bone-density check | Menopause already thins bone; know your baseline |
Because appetite is lower on a GLP-1, protein is the nutrient most likely to fall short, so make it the deliberate priority at every meal. For the full playbook on holding onto lean mass (and avoiding "Ozempic face"), see our guide to keeping muscle on a GLP-1.
Can you take a GLP-1 with HRT in menopause?
In most cases, yes, hormone replacement therapy (HRT) and a GLP-1 can generally be used together, and early data suggest the pairing may help some women lose a bit more weight than the medication alone. In a 2025 Mayo Clinic retrospective study presented to the Endocrine Society, postmenopausal women on tirzepatide plus hormone therapy lost about 17% of their body weight versus about 14% on tirzepatide alone, a promising signal, though it wasn't a randomized trial, so it can't prove HRT caused the difference. The important practical detail is how your HRT is delivered: because GLP-1s slow digestion, transdermal (patch or gel) estrogen and a non-oral progestogen are often preferred over swallowed hormones. HRT is prescribed to manage menopause symptoms, not as a weight-loss drug, and it carries its own risks and benefits based on your history, so keep it a coordinated decision with your menopause provider. We go deeper in GLP-1 + HRT for menopause weight loss.
When should you start?
There's no single "right" age, it's about your health, not the calendar. Many women consider a GLP-1 when weight or metabolic changes around perimenopause and menopause aren't responding to the usual adjustments, and when a clinician judges the medication appropriate for their overall risk profile. What matters more than timing is starting with the protections above in place and with a provider who knows your full picture, including bone and heart health. If side-effect sensitivity is a concern, some midlife women ask about a lower-and-slower approach; read our honest look at microdosing GLP-1s in perimenopause and menopause, and remember that "microdosing" is clinician-supervised and its evidence is still thin.
How Elara helps
Elara is built for this stage of life. Our licensed providers review every patient's full history, including where you are in the menopause transition and your bone and muscle picture, before deciding whether a GLP-1 is appropriate and how to start it. Elara offers branded Wegovy and Zepbound as well as compounded semaglutide and compounded tirzepatide, plus supportive options like B12 for energy when they genuinely fit your plan. Compounded semaglutide starts at $247/month and compounded tirzepatide at $355/month, all-inclusive, medication, provider visit, shipping, ongoing access to the medical team, and the Elara app with recipes and workouts to make the protein-and-strength habit realistic.
Take a free eligibility check on our weight-loss program, a licensed provider reviews every patient. You can also explore Elara's compounded semaglutide program for women or compounded tirzepatide.
Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. They are not "generic" versions of Ozempic, Wegovy, Mounjaro, or Zepbound.
Every GLP-1 also carries a boxed warning for thyroid C-cell tumors and is contraindicated if you or a close relative has had medullary thyroid carcinoma or MEN 2; other cautions include pancreatitis, gallbladder problems, and significant GI effects. GLP-1s are not recommended in pregnancy or while breastfeeding. Talk to a licensed provider about whether one is right for you.
Frequently asked questions
Do GLP-1s work for menopause weight gain? Yes. A 2025 analysis of the SURMOUNT tirzepatide trials found postmenopausal women lost about 23% of their body weight versus roughly 3% on placebo, comparable to younger women. That menopause-stratified data is from tirzepatide; semaglutide isn't broken out the same way but is expected to behave similarly. GLP-1s counter the appetite and insulin-resistance changes that make midlife weight harder to lose. Individual results vary with your full program.
Why is it harder to lose weight in menopause? Falling estrogen shifts fat toward the abdomen (visceral fat), worsens insulin resistance, and accelerates muscle loss. Because muscle burns calories, losing it lowers your resting metabolism, so the same habits that once held your weight steady may no longer work. It's a hormonal and metabolic change, not a lack of effort.
Can you take semaglutide with HRT? In most cases, yes, hormone therapy and a GLP-1 can generally be used together, and early research (a 2025 Mayo Clinic study) suggests the combination may add to weight loss for some women, though it wasn't a randomized trial. Because GLP-1s slow digestion, transdermal (patch or gel) estrogen and a non-oral progestogen are often preferred. HRT has its own risks and benefits, so coordinate both decisions with your clinicians.
Do GLP-1s cause bone loss in menopause? Weight loss of any kind can reduce bone density, and menopause already accelerates bone loss as estrogen falls, so experts flag the overlap as a real caution to manage, though the evidence is still evolving. Resistance training and adequate protein help protect bone and muscle. Ask your provider about a baseline bone-density check.
When should you start a GLP-1 in menopause? There's no set age. Many women consider one when weight or metabolic changes around menopause aren't responding to other adjustments and a clinician judges the medication appropriate for their overall health. What matters most is starting with muscle- and bone-protection in place and with a provider who knows your full history.
The bottom line
Menopause weight gain is a hormonal shift, not a personal failing, and GLP-1 medications work about as well in menopausal women as in younger ones. The honest caveat is that menopause and rapid weight loss can each cost you muscle and bone, so a midlife plan should pair the medication with protein, strength training, and enough nutrition to protect what you have. Bring the whole picture, including bone and hormone health, to a licensed clinician.
References
- NewYork-Presbyterian. "Women in Menopause Benefit From GLP-1 Weight-Loss Medications as Much as Younger Women." https://www.nyp.org/advances/article/women-in-menopause-benefit-from-glp-1-weight-loss-medications-as-much-as-younger-women
- UCHealth Today. "Menopause and GLP-1 weight-loss drugs could cause bone loss." https://www.uchealth.org/today/menopause-and-glp-1-weight-loss-drugs-and-bone-loss/
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity" (STEP 1). New England Journal of Medicine, 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity" (SURMOUNT-1). New England Journal of Medicine, 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
- U.S. Food and Drug Administration. "Wegovy (semaglutide) injection, Prescribing Information" (boxed warning, thyroid C-cell tumors), via DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- U.S. Food and Drug Administration. "Zepbound (tirzepatide) injection, Prescribing Information" (boxed warning, thyroid C-cell tumors). https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s005s006s011s015s019lbl.pdf
- Castaneda R, et al. "Combination of obesity medication tirzepatide and menopause hormone therapy fuels weight loss" (retrospective cohort study presented at ENDO 2025). The Endocrine Society. https://www.endocrine.org/news-and-advocacy/news-room/endo-annual-meeting/endo-2025-press-releases/castaneda-press-release
This article is for general education and is not medical advice. It doesn't replace a conversation with a licensed clinician about your health, medications, or treatment. Reading it doesn't create a doctor-patient relationship. If you have a medical emergency, call 911. See our full Medical Disclaimer.
About compounded medications: Compounded semaglutide and tirzepatide are prepared by a state-licensed compounding pharmacy and prescribed by a licensed clinician when appropriate for you. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. They are not "generic" versions of Ozempic, Wegovy, Mounjaro, or Zepbound. Talk to a licensed clinician about whether a compounded or FDA-approved option is right for you.